SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Clinical trial NCT01261312 · COMPLETED
Trial details
- NCT number
- NCT01261312
- Sponsor
- Astex Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-01-04
- Primary completion
- 2016-07-22
- Enrollment
- 414
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.